move to main move to category
  1. HOME
  2. Corporate Information & SBI Group
  3. SBI Pharmaceuticals

SBI Pharmaceuticals

For Healthy and Enjoyable Life With “5-ALA”

SBI Pharmaceuticals

Focusing on 5-Aminolevlinic acid (5-ALA), SBI Pharmaceuticals develops pharmaceutical, health food, and cosmetic products that contain 5-ALA as the main active ingredient.

Though 5-ALA has long been known as a kind of natural amino acid, it was only recently revealed that 5-ALA is extremely important for respiration and energy generation of living organisms.

Joint research with universities has led to the discovery of 5-ALA's potential in unexplored areas in the fields of metabolism and biological control. Research activities have recently extended to beyond domestic research labs to joint research with foreign universities to constantly discover new applications for 5-ALA.

In the pharmaceutical field, SBI Pharmaceuticals is already marketing ALAGLIO®, a surgical diagnostic drug that facilitates the identifi cation of normal and cancerous cells during cancer surgery. ALAGLIO® utilizes the tendency of a fluorescent metabolite of ALA to accumulate selectively in cancerous cells, which then glow red when exposed to a special blue light. We are also developing a variety of other pharmaceutical products.

In addition, basic and clinical researches are being conducted in various fields overseas as well as in Japan. As part of these efforts to actively promote various 5-ALA related business including the medical field, we have worked together closely with Bahrain in the Middle East.

Focusing on such a promising substance blessed with possible applications in a wider range of fields, we strive to develop the products that serve your healthy and enjoyable life.

* SBI ALApromo changed its corporate name to SBI Pharmaceuticals on April 1, 2012.

Corporate Profile

Company name SBI Pharmaceuticals Co., Ltd.
Principal business Development and manufacture of pharmaceutical, cosmetic, and health food products that contain “5-ALA” (5-Aminolevulinic acid)
Representative Yoshitaka Kitao, Toru Tanaka
Location Izumi Garden Tower, 1-6-1 Roppongi, Minato-ku, Tokyo
Date of establishment April 18, 2008
Paid-in capital 4.7 billion yen
Shareholders * SBI Group 84.89%
COSMO ALA CO.,LTD. 13.83%
URL http://www.sbipharma.co.jp/

* Ownership percentage is based on voting rights. SBI Group's shareholding percentage corresponds to a total percentage based on the IFRS criteria for subsidiary companies and subsidiary funds of the Group.

(As of September 30, 2017)

Corporate Information & SBI Group